What is the current valuation of the France human growth hormone market?

As of 2024, the market valuation was 0.276 USD Billion. Read More

What is the projected market size for the France human growth hormone market by 2035?

The market is projected to reach 0.806 USD Billion by 2035. Read More

What is the expected CAGR for the France human growth hormone market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 10.24%. Read More

Which companies are the key players in the France human growth hormone market?

Key players include Novo Nordisk, Pfizer, Merck KGaA, Boehringer Ingelheim, Ipsen, Sandoz, Ferring Pharmaceuticals, Genentech, and Hikma Pharmaceuticals. Read More

What are the main applications of human growth hormone in France?

Main applications include Growth Hormone Deficiency, Turner Syndrome, Chronic Kidney Disease, Prader-Willi Syndrome, and Idiopathic Short Stature. Read More

How did the market for Growth Hormone Deficiency perform in 2024?

In 2024, the market for Growth Hormone Deficiency was valued at 0.11 USD Billion. Read More

What is the expected market size for Growth Hormone Deficiency by 2035?

The market for Growth Hormone Deficiency is projected to grow to 0.32 USD Billion by 2035. Read More

What distribution channels are utilized in the France human growth hormone market?

Distribution channels include Pharmacies, Online Pharmacies, and Hospital Pharmacies. Read More

What is the market size for homecare applications in 2024?

The homecare application market was valued at 0.0277 USD Billion in 2024. Read More

What are the different routes of administration for human growth hormone in France?

Routes of administration include Subcutaneous Injection, Intravenous Injection, and Intramuscular Injection. Read More

France Human Growth Hormone Market

ID: MRFR/HC/43246-HCR

200 Pages

Satyendra Maurya

Last Updated: April 06, 2026

France Human Growth Hormone Market Research Report By Brand (Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, Skytrofa, Others), By Route of Administration (Subcutaneous, Intramuscular, Intravenous), By Application (Pediatric Growth Hormone Deficiency, Adult Growth Hormone Deficiency, Idiopathic Growth Hormone Deficiency, Small for Gestational Age, Turner Syndrome, Prader-Willi Syndrome, Others) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacy, Specialty Pharmacy) - Growth & Industry Forecast 2025 To 2035

France Human Growth Hormone Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)10.24%

2024 Market Size$ 0.28 Billion

2025 Market Size$ 0.31 Billion

2035 Market Size$ 0.81 Billion

Key Players

Novo Nordisk

Pfizer

Merck KGaA

Boehringer Ingelheim

Ipsen

Sandoz

Trends

Rising Awareness of Growth Hormone Deficiencies
Advancements in Biotechnology
Regulatory Changes and Market Accessibility

Opportunities

Supportive Regulatory Environment
Growing Demand for Anti-Aging Treatments
Technological Innovations in Hormone Therapy

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Growth Hormone Deficiency
  2. 4.1.2 Turner Syndrome
  3. 4.1.3 Chronic Kidney Disease
  4. 4.1.4 Prader-Willi Syndrome
  5. 4.1.5 Idiopathic Short Stature
2. 4.2 Healthcare, BY End Use (USD Billion)
  1. 4.2.1 Hospitals
  2. 4.2.2 Clinics
  3. 4.2.3 Homecare
  4. 4.2.4 Research Laboratories
3. 4.3 Healthcare, BY Route of Administration (USD Billion)
  1. 4.3.1 Subcutaneous Injection
  2. 4.3.2 Intravenous Injection
  3. 4.3.3 Intramuscular Injection
4. 4.4 Healthcare, BY Distribution Channel (USD Billion)
  1. 4.4.1 Pharmacies
  2. 4.4.2 Online Pharmacies
  3. 4.4.3 Hospital Pharmacies
5. 4.5 Healthcare, BY Formulation (USD Billion)
  1. 4.5.1 Lyophilized Powder
  2. 4.5.2 Liquid Solution
  3. 4.5.3 Pre-filled Syringes
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novo Nordisk (DK)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Pfizer (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck KGaA (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Boehringer Ingelheim (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Ipsen (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sandoz (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Ferring Pharmaceuticals (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Genentech (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Hikma Pharmaceuticals (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 FRANCE MARKET ANALYSIS BY APPLICATION
3. 6.3 FRANCE MARKET ANALYSIS BY END USE
4. 6.4 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 FRANCE MARKET ANALYSIS BY FORMULATION
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
17. 6.17 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
19. 6.19 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
21. 6.21 HEALTHCARE, BY FORMULATION, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY FORMULATION, 2024 TO 2035 (USD Billion)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  2. 7.2.2 BY END USE, 2026-2035 (USD Billion)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Billion)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Billion)
  5. 7.2.5 BY FORMULATION, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

France France Human Growth Hormone Market Segmentation

France Human Growth Hormone Market By Application (USD Billion, 2026-2035)

Growth Hormone Deficiency
Turner Syndrome
Chronic Kidney Disease
Prader-Willi Syndrome
Idiopathic Short Stature

France Human Growth Hormone Market By End Use (USD Billion, 2026-2035)

Hospitals
Clinics
Homecare
Research Laboratories

France Human Growth Hormone Market By Route of Administration (USD Billion, 2026-2035)

Subcutaneous Injection
Intravenous Injection
Intramuscular Injection

France Human Growth Hormone Market By Distribution Channel (USD Billion, 2026-2035)

Pharmacies
Online Pharmacies
Hospital Pharmacies

France Human Growth Hormone Market By Formulation (USD Billion, 2026-2035)

Lyophilized Powder
Liquid Solution
Pre-filled Syringes

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”